Disc Medicine Announces $90 Million Series B Financing To Advance Portfolio Of Clinical-Stage Therapies For Hematologic Diseases
Amount Raised
$90 Million
Round Type
Series B
WatertownBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Description
Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, today announced a $90 million Series B financing from a leading syndicate of investors. The financing was led by OrbiMed with participation from new investors Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital, Nantahala Capital Management, Willett Advisors, and Alexandria Venture Investments. Existing investors also participated in the financing, including Atlas Venture, Novo Holdings and Access Biotechnology.
Who to call at Disc, and when
A new round usually means Disc is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Disc raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Disc, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Disc raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansDisc raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.